PrimeX News

S&P 500 Forecast: Elliott Wave Setup Puts $7,551 Breakout and $7,348 Support in Focus
Wed, 08 Jul 2026 21:08:58 GMT
Crocs, Inc. (CROX) Price Forecast: Can This Bullish Pattern Trigger a New Rally?
Wed, 08 Jul 2026 21:00:32 GMT
Gold (XAU/USD) Price Forecast: Resistance Keeps Bears in Control
Wed, 08 Jul 2026 20:53:17 GMT
Natural Gas Price Forecast: Support Test Determines Next Direction
Wed, 08 Jul 2026 20:40:20 GMT
Silver (XAG) Forecast: Silver Market Slides as Oil Tops $79 and Yields Jump
Wed, 08 Jul 2026 20:18:06 GMT
NASDAQ Index, SP500, Dow Jones Forecasts – NASDAQ Rebounds As Traders Shrug Off Geopolitical Risks
Wed, 08 Jul 2026 19:47:14 GMT

From Currencies to Commodities: Leveraging Gold Ratios in Trading
Thu, 25 Jun 2026 12:59:13 GMT
First Light News: Trump Puts Pen to Paper & the Fed Comes in Hawkish
Thu, 18 Jun 2026 08:20:37 GMT
ECB, Bank of England Set to Hold Rates Unchanged Today
Thu, 11 Jun 2026 17:21:35 GMT
Nasdaq 100: Meta Falls as Amazon Slips, Microsoft, Alphabet Diverge
Wed, 29 Apr 2026 21:43:04 GMT
Hungary’s Euro Ambition Is a Long-term Bet Requiring Discipline, Credibility and Integration
Thu, 11 Jun 2026 17:22:50 GMT
A Divided Fed to Continue Favouring Easing Even as the Iran War Raises the Stakes
Thu, 11 Jun 2026 17:20:25 GMT

Seasonality and Event-Driven Trades in ETFs: How to Spot Recurring Trading Opportunities
Fri, 19 Jun 2026 23:26:11 GMT
Building and Risk-Managing Multi-Asset Portfolios with ETFs
Fri, 19 Jun 2026 20:08:58 GMT
What Really Drives ETF Performance: Rebalancing, Dividends, Fees, and Tracking Error
Tue, 23 Jun 2026 13:26:26 GMT
Trading Volume Explained: Why it Matters for Breakouts, Reversals and Trends
Wed, 10 Jun 2026 00:40:01 GMT
RSI Indicator Explained: How to Read Momentum and Time Trades in 2026
Wed, 03 Jun 2026 21:56:39 GMT
Fibonacci Retracements Explained: How to Spot Key Reversal Levels in 2026
Thu, 28 May 2026 12:22:53 GMT

Advertisement

Advertisement

TEVA

Teva Pharmaceutical Industries Limited - ADR

33.24

USD

-1.41

-4.07%

Jul 08, 16:00 UTC -4

Closed

exchange

After-Market

33.75

+0.51

+1.53%

TEVA News & Forecasts

featured

Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript

featured

Zacks Investment Research

Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth

featured

Zacks Investment Research

Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome

featured

The Motley Fool

Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?

featured

The Motley Fool

Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?

featured

Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

featured

Zacks Investment Research

3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

featured

The Motley Fool

Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks

featured

TEVA's Growth Story Is No Longer Just Generic, It's Getting Branded

featured

Zacks Investment Research

TEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EU

featured

The Motley Fool

Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.

featured

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

featured

Zacks Investment Research

TEVA Q1 Earnings Top Estimates, Branded Drugs Drive Revenues, Stock Up

featured

Teva Pharmaceutical Industries Limited (TEVA) Q1 2026 Earnings Call Transcript

featured

CNBC Television

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

featured

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

featured

Zacks Investment Research

Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say

featured

Investors Business Daily

Teva Surges As Its New Growth Strategy Hits A Key Inflection Point

featured

The Motley Fool

Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock.

featured

The Motley Fool

3 Catalysts That Could Send Teva Stock to $40 and Beyond

Advertisement

Advertisement

Advertisement